Comparison of the Treatment Guidelines for Actinic Keratosis: A Critical Appraisal and Review

  title={Comparison of the Treatment Guidelines for Actinic Keratosis: A Critical Appraisal and Review},
  author={Patrick J. Fleming and Stephanie Zhou and R Bobotsis and Charles W. Lynde},
  journal={Journal of Cutaneous Medicine and Surgery},
  pages={408 - 417}
There are currently several reputable guidelines on the treatment of actinic keratosis (AK) from groups in Canada, the United Kingdom, and Europe. These recommendations, based on evidence or expert consensus, offer clinicians a variety of treatment options for the different clinical presentations of AKs. Although the guidelines are similar in some regards, variations exist in treatment options, duration, and strength of recommendation. Some guidelines also lack input on specific therapies and… 

Tables from this paper

Italian expert consensus paper on the management of patients with actinic keratoses
Oral nicotinamide 500 mg twice daily, systemic retinoids and regular sunscreen use were demonstrated to reduce the number of new squamous cell carcinomas in patients with AKs, and Photodynamic therapy is the most studied treatment for AKs on the arms.
A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions
Given the aging population and therefore the increasing incidence of AK and cutaneous field carcinogenesis, further updates on the long-term efficacy of current therapies and new investigational agents are critical to guide treatment choice.
1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses
Tirbanibulin effectively reduces AK burden and recurrence and has a favorable safety profile with mild adverse events, compared with imiquimod, 5-flourouracil, and diclofenac, which can result in necrosis, angioedema, and arthralgias.
Efficacy of topical imiquimod 3.75% in the treatment of actinic keratosis of the scalp in immunosuppressed patients: our case series
Topical Imiquimod 3.75% represents an effective and safe treatment for multiple AK of the scalp also in immunosuppressed patients, and to the best of the knowledge, this is the first report on the use of this drug in this category of subjects.
Swiss (German) Version of the Actinic Keratosis Quality of Life questionnaire
A Swiss (German) version of the AKQoL questionnaire applicable for the population of a university center in Switzerland is culturally adapted and validated to measure and monitor the quality of life in patients with AK.
Intensity of Local Skin Reactions During 5-Fluorouracil Treatment Related to the Number of Actinic Keratosis Lesions: A Post Hoc, Exploratory Analysis
Local skin reactions appeared to be more severe in patients with more than 10 actinic keratosis lesions at baseline than in those with 5 to 10 lesions, and treatment with 5-fluorouracil 4% cream OD was associated with less severe local skin reactions than 5- fluorouredacil 5% BID.
Use and Cost of Actinic Keratosis Destruction in the Medicare Part B Fee-for-Service Population, 2007 to 2015
The findings suggest that actinic keratosis imposes continuously increasing levels of treatment burden in the Medicare fee-for-service population.
Dermoscopic Monitoring for Treatment and Follow-Up of Actinic Keratosis With 5-Aminolaevulinic Acid Photodynamic Therapy
Dermoscopy can be a useful tool for monitoring the skin lesions in patients with actinic keratosis during photodynamic therapy and follow-up, and in the dermoscopic group, 1 of 35 actinic Keratosis lesions showed recurrence of disease after 6 months of treatment.
Healthcare utilization and management of actinic keratosis in primary and secondary care: a complementary database analysis
The high prevalence of actinic keratosis (AK) requires the optimal use of healthcare resources to improve patient care and reduce unnecessary hospital admissions.


Actinic Keratosis Clinical Practice Guidelines: An Appraisal of Quality
The Cancer Council of Australia/Australian Cancer Network guideline had the highest mean scores and was the only guideline to include a systematic review, include an evidence rating for recommendations, and report conflicts of interest and funding sources.
Primary Care Review of Actinic Keratosis and Its Therapeutic Options: A Global Perspective
The objective of this review is to examine the therapeutic options and management of AK globally, particularly in Australia, Canada, and the United Kingdom.
Current issues in the management of actinic keratosis.
The paradigm shift in treating actinic keratosis: a comprehensive strategy.
Important considerations when developing a comprehensive treatment plan include patient risk factors; the number and location of AK lesions; strategies for minimizing sun exposure; and the mechanism of action, clearance rate, adverse effect pro!le, and application of local and topical therapies.
Effectiveness of 5‐fluorouracil treatment for actinic keratosis – a systematic review of randomized controlled trials
Despite the widespread use of 5-FU to treat AK, the evidence supporting its use has not been reviewed systematically or appraised critically, unlike that for imiquimod, and to identify areas in which further research is needed.
Evidence‐ and consensus‐based (S3) Guidelines for the Treatment of Actinic Keratosis – International League of Dermatological Societies in cooperation with the European Dermatology Forum – Short version
Actinic keratosis (AK) is a frequent health condition attributable to chronic exposure to ultraviolet radiation. Several treatment options are available and evidence based guidelines are missing.
Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses
Options for the management of Actinic keratosis and cheilitis include surgical removal, topical treatment, and photodynamic therapy, which may be used in case of inadequate response.
British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017
British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017 D. de Berker, J.M. McGregor, M.F. Mohd Mustapa, L.S. Exton and B.R. Hughes Bristol Dermatology
Ingenol mebutate gel for actinic keratosis.
Ingenol mebutate gel applied topically for 2 to 3 days is effective for field treatment of actinic keratoses, and adverse events were generally mild to moderate in intensity and resolved without sequelae.